The search for blood biomarkers useful in treating atopic dermatitis patients.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2024-12-16 DOI:10.1080/17512433.2024.2438192

Kenji Izuhara, Satoshi Nunomura, Takeshi Nakahara, Daisuke Onozuka

{"title":"The search for blood biomarkers useful in treating atopic dermatitis patients.","authors":"Kenji Izuhara, Satoshi Nunomura, Takeshi Nakahara, Daisuke Onozuka","doi":"10.1080/17512433.2024.2438192","DOIUrl":null,"url":null,"abstract":"Introduction: Atopic dermatitis (AD) is diagnosed based on clinical signs and symptoms as well as on a clinical course lacking distinct laboratory or histological features; however, the recent appearance of molecularly targeted drugs against AD urges us to try to discover and develop biomarkers useful for treating AD patients.Areas covered: This article commenced with a targeted PubMed search using 'atopic dermatitis' and 'biomarker' as keywords. We combined the findings from the B-PAD study that we have recently published and summarized data, particularly those recently published.Expert opinion: Many cells and molecules are listed as potential biomarkers of AD, most of which are type 2 mediators. Among them, CCL17/TARC is now thought to be the most reliable biomarker of AD. During the B-PAD study, we recently found that three biomarkers - squamous cell carcinoma antigen 2 (SCCA2), CCL26/eotaxin-3, and lactose dehydrogenase (LDH) - are better able than CCL17/TARC to assess the clinical severity and disease activity of AD. Moreover, although several biomarkers showed good ability to monitor the efficacy of molecularly targeted drugs against AD. More studies on the discovery and development of biomarkers of AD are awaited to refine treatments for AD patients.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-10"},"PeriodicalIF":3.6000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2024.2438192","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Atopic dermatitis (AD) is diagnosed based on clinical signs and symptoms as well as on a clinical course lacking distinct laboratory or histological features; however, the recent appearance of molecularly targeted drugs against AD urges us to try to discover and develop biomarkers useful for treating AD patients.

Areas covered: This article commenced with a targeted PubMed search using 'atopic dermatitis' and 'biomarker' as keywords. We combined the findings from the B-PAD study that we have recently published and summarized data, particularly those recently published.

Expert opinion: Many cells and molecules are listed as potential biomarkers of AD, most of which are type 2 mediators. Among them, CCL17/TARC is now thought to be the most reliable biomarker of AD. During the B-PAD study, we recently found that three biomarkers - squamous cell carcinoma antigen 2 (SCCA2), CCL26/eotaxin-3, and lactose dehydrogenase (LDH) - are better able than CCL17/TARC to assess the clinical severity and disease activity of AD. Moreover, although several biomarkers showed good ability to monitor the efficacy of molecularly targeted drugs against AD. More studies on the discovery and development of biomarkers of AD are awaited to refine treatments for AD patients.

查看原文本刊更多论文

对治疗特应性皮炎患者有用的血液生物标志物的研究。

引言：特应性皮炎（AD）的诊断是基于临床体征和症状，以及缺乏明确的实验室或组织学特征的临床病程；然而，近年来针对AD的分子靶向药物的出现促使我们尝试发现和开发可用于治疗AD患者的生物标志物。涵盖领域：本文以“特应性皮炎”和“生物标志物”为关键词进行了有针对性的PubMed搜索。我们结合了最近发表的B-PAD研究结果并总结了数据，特别是最近发表的数据。专家意见：许多细胞和分子被列为AD的潜在生物标志物，其中大多数是2型介质。其中，CCL17/TARC目前被认为是AD最可靠的生物标志物。在B-PAD研究中，我们最近发现三种生物标志物——鳞状细胞癌抗原2 （SCCA2）、CCL26/eotaxin-3和乳糖脱氢酶（LDH）——比CCL17/TARC更能评估AD的临床严重程度和疾病活动性。此外，尽管一些生物标志物显示出良好的能力来监测分子靶向药物对AD的疗效。更多的阿尔茨海默病生物标志物的发现和开发有待研究，以完善阿尔茨海默病患者的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.